References
1. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther . 2015;98(1):19-24.
2. Brunet M, van Gelder T, Åsberg A, et al. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit . 2019;41(3):261-307.
3. Schumacher L, Leino AD, Park JM. Tacrolimus intrapatient variability in solid organ transplantation: A multiorgan perspective.Pharmacotherapy . 2021;41(1):103-18.
4. Mendoza Rojas A, Hesselink DA, van Besouw NM, et al. Impact of low tacrolimus exposure and high tacrolimus intra-patient variability on the development of de novo anti-HLA donor-specific antibodies in kidney transplant recipients. Expert Rev Clin Immunol . 2019;15(12):1323-31.
5. Leino AD, King EC, Jiang W, et al. Assessment of tacrolimus intrapatient variability in stable adherent transplant recipients: Establishing baseline values. Am J Transplant . 2019;19(5):1410-20.
6. Whalen HR, Glen JA, Harkins V, et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.Transplantation . 2017;101(2):430-6.
7. Gallagher HM, Sarwar G, Tse T, et al. Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. J Heart Lung Transplant . 2015;34(11):1442-8.
8. Kao CC, Segraves J, Parulekar AD. Tacrolimus monitoring parameters are not associated with acute cellular rejection following lung transplantation. Eur J Clin Pharmacol . 2021;77(1):63-9.
9. Ensor CR, Iasella CJ, Harrigan KM, et al. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant . 2018;18(6):1527-33.
10. Garrity ER, Jr., Hertz MI, Trulock EP, et al. Suggested guidelines for the use of tacrolimus in lung-transplant recipients. J Heart Lung Transplant . 1999;18(3):175-6.
11. Gray AL, Mulvihill MS, Hartwig MG. Lung transplantation at Duke.J Thorac Dis . 2016;8(3):E185-96.
12. Neurohr C, Huppmann P, Zimmermann G, et al. Tacrolimus and mycophenolate mofetil as first line immunosuppression after lung transplantation. Transpl Int . 2009;22(6):635-43.
13. Du WW, Wang XX, Zhang D, et al. Retrospective analysis on incidence and risk factors of early onset acute kidney injury after lung transplantation and its association with mortality. Ren Fail . 2021;43(1):535-42.
14. Sikma MA, Hunault CC, van de Graaf EA, et al. High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury. Eur J Clin Pharmacol . 2017;73(5):573-80.
15. Ryu JH, Choi S, Lee HJ, et al. Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients. Ann Thorac Med . 2019;14(3):186-91.
16. Stefanović NZ, Veličković-Radovanović RM, Danković KS, et al. Combined Effect of Inter- and Intrapatient Variability in Tacrolimus Exposure on Graft Impairment Within a 3-Year Period Following Kidney Transplantation: A Single-Center Experience. Eur J Drug Metab Pharmacokinet . 2020;45(6):749-60.
17. Park Y, Lee H, Eum SH, et al. Combined impact of the inter and intra-patient variability of tacrolimus blood level on allograft outcomes in kidney transplantation. Front Immunol . 2022;13:1037566.
18. Seibert SR, Schladt DP, Wu B, et al. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients. Clin Transplant . 2018;32(12):e13424.
19. Baghai Arassi M, Gauche L, Schmidt J, et al. Association of intraindividual tacrolimus variability with de novo donor-specific HLA antibody development and allograft rejection in pediatric kidney transplant recipients with low immunological risk. Pediatr Nephrol . 2022;37(10):2503-14.
20. Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT.J Heart Lung Transplant . 2019;38(5):493-503.
21. Darley DR, Carlos L, Hennig S, et al. Tacrolimus exposure early after lung transplantation and exploratory associations with acute cellular rejection. Eur J Clin Pharmacol . 2019;75(7):879-88.
22. Miano TA, Flesch JD, Feng R, et al. Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury. Clin Pharmacol Ther . 2020;107(2):462-70.
23. Destere A, Premaud A, Monchaud C, et al. Longitudinal Exposure to Tacrolimus and New-Onset Diabetes Mellitus in Renal Transplant Patients.Ther Drug Monit . 2023;45(1):102-9.
24. Gonzales HM, McGillicuddy JW, Rohan V, et al. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation. Am J Transplant . 2020;20(8):1969-83.
25. Coste G, Lemaitre F. The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas. Pharmaceutics . 2022;14(2).
26. Oetting WS, Schladt DP, Guan W, et al. Genomewide Association Study of Tacrolimus Concentrations in African American Kidney Transplant Recipients Identifies Multiple CYP3A5 Alleles. Am J Transplant . 2016;16(2):574-82.
27. Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit . 2012;34(6):680-5.
28. Nuchjumroon A, Vadcharavivad S, Singhan W, et al. Comparison of Tacrolimus Intra-Patient Variability during 6-12 Months after Kidney Transplantation between CYP3A5 Expressers and Nonexpressers. J Clin Med . 2022;11(21).